Daniel B Horton1, Jomaira Salas2, Aleksandra Wec3, Melanie Kohlheim4, Pooja Kapadia5, Timothy Beukelman6, Alexis Boneparth7, Ky Haverkamp8, Melissa L Mannion6, L Nandini Moorthy9, Sarah Ringold10, Marsha Rosenthal11. 1. Rutgers Robert Wood Johnson Medical School and Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, New Brunswick, New Jersey, and Rutgers School of Public Health, Piscataway, New Jersey. 2. Rutgers University, New Brunswick, New Jersey. 3. Mathematica Policy Research, Princeton, New Jersey. 4. Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, Ohio. 5. Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey. 6. University of Alabama at Birmingham. 7. Columbia University Medical Center, New York, New York. 8. University of Washington School of Medicine, Seattle. 9. Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey. 10. Seattle Children's Hospital, Seattle, Washington. 11. Institute for Health, Health Care Policy and Aging Research, New Brunswick, New Jersey.
Abstract
OBJECTIVE: Improved treatments for juvenile idiopathic arthritis (JIA) have increased remission rates. We conducted this study to investigate how patients and caregivers make decisions about stopping medications when JIA is inactive. METHODS: We performed a mixed-methods study of caregivers and patients affected by JIA, recruited through social media and flyers, and selected by purposive sampling. Participants discussed their experiences with JIA, medications, and decision-making through recorded telephone interviews. Of 44 interviewees, 20 were patients (50% ages <18 years), and 24 were caregivers (50% caring for children ages ≤10 years). We evaluated characteristics associated with high levels of reported concerns about JIA or medicines using Fisher's exact testing. RESULTS: Decisions about stopping medicines were informed by competing risks between disease activity and treatment. Participants who expressed more concerns about JIA were more likely to report disease-related complications (P = 0.002) and more motivated to continue treatment. However, participants expressing more concern about medicines were more likely to report treatment-related complications (P = 0.04) and felt more compelled to stop treatment. Additionally, participants considered how JIA or treatments facilitated or interfered with their sense of normalcy and safety, expressed feelings of guilt and regret about previous or potential adverse events, and reflected on uncertainty and unpredictability of future harms. Decision-making was also informed by trust in rheumatologists and other information sources (e.g., family and online support groups). CONCLUSION: When deciding whether to stop medicines whenever JIA is inactive, patients and caregivers weigh competing risks between disease activity and treatment. Based on our results, we suggest specific approaches for clinicians to perform shared decision-making regarding stopping medicines for JIA.
OBJECTIVE: Improved treatments for juvenile idiopathic arthritis (JIA) have increased remission rates. We conducted this study to investigate how patients and caregivers make decisions about stopping medications when JIA is inactive. METHODS: We performed a mixed-methods study of caregivers and patients affected by JIA, recruited through social media and flyers, and selected by purposive sampling. Participants discussed their experiences with JIA, medications, and decision-making through recorded telephone interviews. Of 44 interviewees, 20 were patients (50% ages <18 years), and 24 were caregivers (50% caring for children ages ≤10 years). We evaluated characteristics associated with high levels of reported concerns about JIA or medicines using Fisher's exact testing. RESULTS: Decisions about stopping medicines were informed by competing risks between disease activity and treatment. Participants who expressed more concerns about JIA were more likely to report disease-related complications (P = 0.002) and more motivated to continue treatment. However, participants expressing more concern about medicines were more likely to report treatment-related complications (P = 0.04) and felt more compelled to stop treatment. Additionally, participants considered how JIA or treatments facilitated or interfered with their sense of normalcy and safety, expressed feelings of guilt and regret about previous or potential adverse events, and reflected on uncertainty and unpredictability of future harms. Decision-making was also informed by trust in rheumatologists and other information sources (e.g., family and online support groups). CONCLUSION: When deciding whether to stop medicines whenever JIA is inactive, patients and caregivers weigh competing risks between disease activity and treatment. Based on our results, we suggest specific approaches for clinicians to perform shared decision-making regarding stopping medicines for JIA.
Authors: Carol A Wallace; Edward H Giannini; Bin Huang; Lukasz Itert; Nicolino Ruperto Journal: Arthritis Care Res (Hoboken) Date: 2011-07 Impact factor: 4.794
Authors: Viviane Adam; Yvan St-Pierre; Bruno Fautrel; Ann E Clarke; Ciarán M Duffy; John R Penrod Journal: J Rheumatol Date: 2005-02 Impact factor: 4.666
Authors: Lilian H D van Tuyl; Sarah Hewlett; Martina Sadlonova; Bev Davis; Caroline Flurey; Wijnanda Hoogland; John Kirwan; Tessa Sanderson; Dirkjan van Schaardenburg; Marieke Scholte-Voshaar; Josef Smolen; Tanja Stamm; Maarten Boers Journal: Ann Rheum Dis Date: 2014-02-12 Impact factor: 19.103
Authors: Nicholas Knowlton; Kaiyu Jiang; Mark Barton Frank; Amita Aggarwal; Carol Wallace; Ryan McKee; Brad Chaser; Catherine Tung; Laura Smith; Yanmin Chen; Jeanette Osban; Kathleen O'Neil; Michael Centola; Julie L McGhee; James N Jarvis Journal: Arthritis Rheum Date: 2009-03
Authors: Ellen A Lipstein; William B Brinkman; Jessica Sage; Carole M Lannon; Esi Morgan Dewitt Journal: Pediatr Rheumatol Online J Date: 2013-09-30 Impact factor: 3.054
Authors: Joachim Gerss; Monika Tedy; Ariane Klein; Gerd Horneff; Maria Miranda-Garcia; Christoph Kessel; Dirk Holzinger; Valda Stanevica; Joost F Swart; David A Cabral; Hermine I Brunner; Dirk Foell Journal: Ann Rheum Dis Date: 2022-03-08 Impact factor: 27.973